Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409219 | 1.00 | ABL1 (0.36) | ABL1MKNK1MKNK2DHODHCYP1A2 | |
| SCHEMBL2417330 | 0.89 | PRMT5 (0.40) | DHODHPRMT5WDR77 | |
| SCHEMBL2417328 | 0.89 | PRMT5 (0.40) | DHODHPRMT5WDR77 | |
| SCHEMBL2411516 | 0.87 | DHFR (0.37) | DHODHPDE10AADORA3DYRK1ACLK4 | |
| SCHEMBL2411520 | 0.87 | DHFR (0.37) | DHODHPDE10AADORA3DYRK1ACLK4 | |
| SCHEMBL315039 | 0.87 | ABL1 (0.35) | ABL1MKNK1MKNK2PDE10A | |
| SCHEMBL315038 | 0.87 | ABL1 (0.35) | ABL1MKNK1MKNK2PDE10A | |
| SCHEMBL2410624 | 0.87 | CTSA (0.36) | DHODHPDE10AADORA3 | |
| SCHEMBL2410623 | 0.87 | CTSA (0.36) | DHODHPDE10AADORA3 | |
| SCHEMBL2408740 | 0.84 | CYP2A6 (0.37) | ABL1DHODHMGLLPDE10AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | ABL1 2708/4885MKNK1 2501/4885MKNK2 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.